Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Terbuch, A; Posch, F; Partl, R; Zurl, B; Bauernhofer, T; Pichler, M; Szkandera, J; Hutterer, GC; Pummer, K; Kapp, KS; Stöger, H; Gerger, A; Stotz, M.
Risk stratification for febrile neutropenia in patients with testicular germ cell tumors.
Cancer Med. 2018; 7(2):508-514
Doi: 10.1002/cam4.1317
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Gerger Armin
- Terbuch Angelika
- Co-Autor*innen der Med Uni Graz
- Bauernhofer Thomas
- Hutterer Georg
- Kapp Karin S.
- Partl Richard
- Pichler Martin
- Posch Florian
- Pummer Karl
- Stöger Herbert
- Stotz Michael
- Szkandera Joanna
- Zurl Brigitte
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The aim of this study was to detect risk factors for febrile neutropenia (FN) in patients with testicular germ cell tumors (TGCT). In this retrospective cohort study at the Medical University of Graz, we included 413 consecutive TGCT patients who received adjuvant or curative treatment with cisplatin-based chemotherapy. FN occurred in 70 (16.9%) of 413 patients. In univariable logistic regression, higher age (odds ratio (OR) per 5 years = 1.17, 95% CI: 1.02-1.35, P = 0.022), reduced performance status (PS) (OR = 2.73, 1.47-5.06, P = 0.001), seminomatous histology (OR = 2.19, 1.26-3.78, P = 0.005), poor IGCCCG risk class (OR = 4.20, 1.71-10.33, P = 0.002), and prior radiotherapy (pRTX) (OR = 8.98, 2.09-38.61, P = 0.003) were associated with a higher risk of FN. In multivariable analysis adjusting for age and risk classification, only poor PS (OR = 2.06, 1.05-4.03, P = 0.035), seminomatous histology (OR = 2.08, 1.01-4.26, P = 0.047), and pRTX (OR = 7.31, 1.61-33.17, P = 0.010) prevailed. In the subgroup of seminoma patients (n = 104), only pRTX predicted for FN risk (OR = 5.60, 1.24-25.34, P = 0.025). Five of eight seminoma patients with pRTX developed FN (63%), as compared to 22 FN cases (23%) in the 96 seminoma patients without pRTX (P = 0.027). The eight seminoma patients who received pRTX had significantly lower pre-chemo white blood counts (4.7 vs. 6.5 G/L), neutrophil counts (3.2 vs. 4.3 G/L), and platelet counts (185 vs. 272 G/L) than patients without pRTX (all P < 0.0001). TGCT patients with a reduced performance status or who had been previously treated with radiotherapy have an increased risk for neutropenic fever during chemotherapy. © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Chemoradiotherapy - adverse effects
- Cisplatin - administration & dosage
- Cisplatin - adverse effects
- Febrile Neutropenia - diagnosis
- Febrile Neutropenia - etiology
- Humans -
- Logistic Models -
- Male -
- Multivariate Analysis -
- Neoplasms, Germ Cell and Embryonal - complications
- Neoplasms, Germ Cell and Embryonal - therapy
- Outcome Assessment (Health Care) - methods
- Outcome Assessment (Health Care) - statistics & numerical data
- Retrospective Studies -
- Risk Assessment - methods
- Risk Assessment - statistics & numerical data
- Risk Factors -
- Testicular Neoplasms - complications
- Testicular Neoplasms - therapy
- Find related publications in this database (Keywords)
- testicular cancer
- febrile neutropenia
- risk factors
- radiotherapy
- chemotherapy